|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Additional conditions recognized in this trial | ||||
| Brain Neoplasms | |||||
| Central Nervous System Neoplasms | |||||
| Nervous System Neoplasms | |||||
| 2 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Nervous System Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| procarbazine hydrochloride | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Procarbazine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Cancer Institute (NCI) | |||||